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Primary aldosteronism (PA) was first reported by Jerome Conn from the University of 
Michigan1 and is characterized by hypertension with excessive, autonomous production of 
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aldosterone relative to suppressed renin levels.2 Once thought to be a rare condition, it is 
now known to be the most common form of endocrine hypertension. The overall prevalence 
in the general hypertensive population was recently demonstrated to be 5.9% increasing 
with the severity of hypertension (3.9-11.8%, grade I-III hypertension)3 to as much as 20% in 
patients with resistant hypertension.4 An early diagnosis followed by correct treatment has 
an important impact on clinical outcome because it can reverse the increased risk of 
cardiovascular and cerebrovascular complications associated with PA.5,6  
PA can be familial caused by either of the 4 currently recognized subtypes (Familial 
Hyperaldosteronism types I-IV) or arise sporadically in which the aldosterone excess is 
unilateral [usually caused by an aldosterone-producing adenoma (APA)] or bilateral [usually 
caused by bilateral adrenal hyperplasia (BAH)]. The unilateral and bilateral forms of PA 
should be differentiated because a patient with unilateral APA is most appropriately treated 
by adrenalectomy,2 which normalizes or improves blood pressure in 84% of cases,7 and a 
patient with BAH is treated in almost all cases with a mineralocorticoid antagonist.2 Details 
for the diagnosis of PA and recommendations for the protocol and interpretation of adrenal 
venous sampling are described in detail elsewhere.8-10  
Until 2011, the genetic basis of PA was largely unknown when in an unprecedented 
development germline mutations causing new familial forms of PA and somatic mutations 
driving aldosterone excess in the majority of sporadic unilateral APAs were uncovered. The 
development of specific monoclonal antibodies to the highly homologous human CYP11B2 
and CYP11B1 enzymes identified novel histological structures and evolved our 
understanding of the pathophysiology of aldosterone overproduction. Herein we 
comprehensively cover what is old and what is new in the rapidly developing field of the 
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pathogenesis of PA and focus on discoveries from genetics to histopathology of the last 3 
years. 
Familial forms of hyperaldosteronism 
Familial hyperaldosteronism is estimated to account for less than 6% of all referred 
cases of PA.11 Familial hyperaldosteronism type I (FH type I, previously referred to as 
glucocorticoid-remediable aldosteronism) was the first genetically-defined form of human 
hypertension.12  The molecular basis of FH type II is unknown whereas the genetic 
determinants of FH types III and IV were identified with the advent of next-generation 
sequencing methods. The genetic basis and clinical phenotype of each of the known familial 
forms of PA are summarized in table 1. 
Familial hyperaldosteronism type I  
Familial hyperaldosteronism type I (FH type I) accounts for less than 1% of diagnosed 
cases of PA.11 This disorder displays a high degree of inter- and intra-familial phenotypic 
variability but is usually an early-onset form of hypertension associated with a high incidence 
of stroke. FH type I is caused by a chimaeric gene that comprises the promoter of the 11β-
hydroxylase gene (CYP11B1) fused to the coding region of the aldosterone synthase gene 
(CYP11B2).12 Gene expression of the CYP11B1/CYP11B2 chimera is therefore regulated by 
adrenocorticotropic hormone, as for CYP11B1, and not by angiotensin II like CYP11B2. Unlike 
wild-type CYP11B2, the expression of aldosterone synthase from the chimaeric gene is 
suppressed by glucocorticoids, such as dexamethasone, because they suppress 
adrenocorticotropic hormone. CYP11B2 expression is normally restricted to the zona 
glomerulosa (zG) whereas patients with FH type I express the chimaeric gene, and the coding 
region of aldosterone synthase in the zona fasciculata (zF).12 Aldosterone synthase activity is 
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thus co-localized with cortisol that can be metabolized further by the 18-hydroxylase and 18-
oxidase activities of aldosterone synthase to overproduce the hybrid steroids 18-
hydroxycortisol and 18-oxocortisol as is characteristic of this condition.12  
Familial hyperaldosteronism type II  
The clinical and biochemical phenotype of FH type II is indistinguishable from 
sporadic PA11 and is not suppressible by glucocorticoids.13 FH type II is diagnosed when at 
least two family members present with PA who are negative for the chimeric gene which 
causes FH type I, and for FH type III and FH type IV germline mutations (described in more 
detail later). The prevalence of FH type II is difficult to evaluate considering the high 
prevalence of hypertension in the adult population14 and the prevalence of PA in the general 
population with hypertension3 and therefore the chance finding of 2 or more adult family 
members with a diagnosis of PA should be considered. Nonetheless, an estimated 
prevalence has been reported as 3.2-5.5% of all cases of PA.10,11,15 Although an association of 
FH type II with a genetic locus on chromosomal region 7p22 has been reported for some 
affected families,16-18 no mutations in candidate genes have been identified to date despite 
direct Sanger sequencing of multiple candidate genes and next generation sequencing of the 
linked locus and therefore the genetic basis of FH type II remains unknown.10 
Familial hyperaldosteronism type III associated with KCNJ5 mutations 
Familial hyperaldosteronism type III (FH type III) was first described by Geller et al.19 
in 3 family members, the male index case and his 2 daughters, who presented with 
hyperaldosteronism and severe hypertension from childhood with hypokalemia and high 
levels of the hybrid steroids 18-oxocortisol and 18-hydroxycortisol.19 The index case 
originally came to medical attention as a 5 year old some 50 years previously; treatment 
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required bilateral adrenalectomy at 9 years of age which normalized blood pressure and the 
serum K+ concentration within 1 week of surgery.19,20 The daughters were treated similarly: 
the resected adrenals from all 3 patients were greatly enlarged and showed extensive 
hyperplasia of the zF.  
The arrival of next-generation sequencing technology later revealed the presence of 
a germline heterozygous mutation in the KCNJ5 gene (encoding the G protein-activated 
inward rectifier potassium channel 4, GIRK4) that associated with the disorder in both father 
and daughters.21 The mutated K+ channel GIRK4 p.Thr158Ala) displayed a loss of selectivity 
for K+ and an increase in Na+ conductance that depolarizes the cell membrane.21 In zG cells, 
membrane depolarization causes the opening of voltage-dependent Ca2+ channels and Ca2+ 
influx which activates Ca2+ signaling pathways and leads to an increase in aldosterone 
production.22,23 Since this original case, other families with FH type III and patients with 
germline KCNJ5 mutations have been described with a clinical phenotype ranging from mild 
to severe (Table 1; Figure 1).  
Familial hyperaldosteronism type IV associated with CACNA1H mutations 
A new familial form of early-onset hyperaldosteronism has been described recently 
(Familial hyperaldosteronism type IV, FH type IV) and is caused by a germline mutation in 
the CACNA1H gene that encodes the T-type (low voltage activated) Ca2+ channel Cav3.2 
(Cav3.2 p.Met1549Val).24 Gain-of-function mutations in CACNA1H have previously been 
associated with epilepsy, seizures and autism.25,26 Scholl et al. reported 5 unrelated 
individuals with early-onset PA with identical Met1549Val mutations.24 Genetic analyses of 
the patients’ families showed that 1 mutation occurred de novo and 4 occurred in the 
germline. In some kindreds, the Cav3.2 p.Met1549Val variant segregated with the 
presentation of early-onset PA with severe hypertension; in another, the phenotype 
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displayed an incomplete penetrance with an intra-familial clinical presentation that varied 
from asymptomatic adults to the early-onset phenotype.24,27 This apparent incongruence 
with the autosomal dominant pattern of inheritance is presumably due to differences in age 
or to other genetic and environmental factors.27 
The physiology of the Cav3.2 p.Met1549Val channel was studied by patch clamp 
recordings of whole human embryonic kidney 293T cells expressing either the mutated 
channel or the wild-type Cav3.2 channel. Cav3.2 p.Met1549Val displayed a markedly slower 
channel inactivation and a shift of activation to less depolarizing potentials.24 The 
Met1549Val mutated form of Cav3.2 thus permits an increased Ca2+ influx that in the 
steroidogenic cell lines NCI H295R and HAC 15, as for mutated GIRK4 channels that likewise 
cause an influx of Ca2+, result in an increased expression of the CYP11B2 gene and 
aldosterone production.28  
A de novo mutation affecting the same residue, Cav3.2 p.Met1549Ile, was identified 
shortly after in a study that reported 4 different germline CACNA1H mutations.29 The 
Met1549Ile substitution was associated with early onset PA and multiplex developmental 
disorder (Table 1). The same study also reported Cav3.2 p.Ser196Leu and p.Pro2083Leu 
mutations associated with familial hyperaldosteronism and found a germline Cav3.2 
p.Val1951Glu mutation in a patient with sporadic APA who was successfully treated by 
unilateral adrenalectomy.29  
 
 
Germline CACNA1D mutations associated with primary aldosteronism with seizures and 
neurologic abnormalities (PASNA) 
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In an attempt to identify new germline mutations associated with PA, candidate 
genes with recurring somatic APA mutations were sequenced in 100 patients with early-
onset PA.30 This approach identified 2 patients with de novo mutations in CACNA1D that 
encodes Cav1.3, a subunit of an L-type (high-voltage activated) Ca2+ channel.30 The two 
different mutations- Cav1.3 p.Gly403Asp and p.Ile770Met- affect amino acid residues of 
Cav1.3 that are also substituted in sporadic APA (described later) with the latter identical to a 
somatic APA mutation. Unlike the somatic variants, the germline mutations cause an 
extreme phenotype, with early onset severe hypertension and hyperaldosteronism and a 
diagnosis in both patients of neurologic abnormalities that include cerebral palsy and 
seizures referred to as PASNA.27,30  
Missense de novo mutations in Cav1.3 p.Ala749Gly, p.Gly407Arg and p.Val401Leu 
have also been identified in patients with autism spectrum disorder. These patients 
additionally presented with epilepsy and had a clinical phenotype resembling that of 
patients with PASNA.31,32 Characterization of the electrophysiological effects incurred by the 
mutations was demonstrated by patch clamp recordings in vitro. All 3 mutations confer a 
gain-of-function phenotype with a predicted increase in Ca2+ inward currents31,32 which 
would be expected to result in elevated plasma aldosterone concentrations in these patients 
but regrettably, these data are unavailable. 
Germline KCNJ5 mutations associated with sporadic primary aldosteronism 
Germline KCNJ5 mutations were identified in 3 of 251 patients with a florid form of sporadic 
BAH.33 The mutations (p.Arg52His, p.Glu246Lys and p.Gly247Arg) were located at some 
distance from the selectivity filter of the GIRK4 K+ channel. Despite this, the Arg52His and 
Glu246Lys mutations caused cell depolarization and increased aldosterone production in 
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vitro in contrast to the Gly247Arg mutation that had no functional effect. A rare 
nonsynonymous single-nucleotide polymorphism rs7102584 was also identified in 12 of 251 
white Australasian patients (5%) with PA compared with 22 of 1075 individuals (2%) in the 
international 1000 genomes cohort. In the 12 patients with PA carrying the rs7102584 
(p.Glu282Gln) polymorphism, 9 were diagnosed with BAH and 3 with APA.33  
Sporadic forms of hyperaldosteronism caused by somatic mutations 
Over half of APAs carry somatic gain-of-function mutations in genes encoding ion 
channels or transporters  (KCNJ5, CACNA1D, ATP1A1, ATP2B3) that can account for excessive 
production of aldosterone. Somatic mutations have also been described in APA that are 
found in cortisol-producing adenomas (CTNNB1, PRKACA and GNAS) although PRKACA and 
GNAS mutations are rare in APA. The somatic APA mutations reported to date are listed in 
Table S1.  
Somatic KCNJ5 mutations in APA 
The original somatic APA mutations described by Choi21 in the KCNJ5 gene cause 
GIRK4 p.Gly151Arg and p.Leu168Arg substitutions in or near the pore of the channel, 
respectively. Both mutations, as for others described subsequently, disturb the selectivity 
properties of the channel as for the p.Thr158Ala mutation associated with FH type III 
described above. At least 17 somatic APA KCNJ5 mutations have been described to date (Fig. 
1, Table S1), but the p.Gly151Arg and p.Leu168Arg substitutions predominate accounting for 
all 34% of APA with GIRK4 mutations of 380 APA recruited through the European Network 
for the Study of Adrenal Tumours34 (ENS@T, http://www.ensat.org) and 47% of APA in an 
international series of 351 APA.35 Somatic KCNJ5 mutations in APA are more frequent in 
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women than in men and compared to non-carriers, are associated with a more pronounced 
hyperaldosteronism, a younger age and larger tumor size.34,36  
The overall prevalence of APA with KCNJ5 mutations was determined in a meta-
analysis of 1636 patients as 43% (range 12-80%) with a higher reported frequency in Japan 
and China compared to European countries.36 Because patients with APA carrying a KCNJ5 
mutation have higher concentrations of the aforementioned hybrid steroid 18-oxocortisol in 
peripheral blood,37 the reported predominance of APA with a KCNJ5 mutation in patients 
from Japan explains the utility of using 18-oxocortisol in peripheral plasma as a potential 
biomarker to differentiate patients with APA from those with BAH38 whereas this is not 
useful in patients from Europe.39 However, the measurement of a panel of 7 steroids, that 
includes the hybrid steroids 18-oxocortisol and 18-hydroxycortisol, in peripheral plasma by 
liquid chromatography-tandem mass spectrometry correctly classified 92% of 79 patients 
with APA according to genotype with a correct call for 26 of 27 patients with APA with a 
KCNJ5 mutation.37  
In a recent development, macrolide antibiotics were identified as selective inhibitors 
of GIRK4 p.Gly151Arg and p.Leu168Arg compared with the wild-type GIRK4 channel and the 
macrolide compound roxithromycin ablated CYP11B2 gene expression and inhibited 
aldosterone production induced by the expression of either GIRK4  p.Gly151Arg or 
p.Leu168Arg in steroidogenic cell lines.40 Macrolides have a potential use in the diagnosis of 
patients with an APA carrying a mutated GIRK4 channel by measuring drug-induced 
decreases in aldosterone concentrations- possibly in tandem with peripheral venous steroid 
profiling- and in their treatment. 
Somatic ATP1A1 and ATP2B3 mutations in APA 
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Shortly following the discovery of KCNJ5 mutations, somatic APA mutations were 
described in the ATP1A1 and ATP2B3 genes, encoding Na+/K+-ATPase 1 and Ca2+-ATPase 3, 
respectively,41,42 that combined account for 7% of APA in patients of European ancestry and 
can result in an increase in CYP11B2 gene expression and aldosterone production43,44 (Table 
S1 lists the ATP1A1/ATP2B3 mutations described to date). APA mutations in ion transporters 
and channels were thought to share a common mechanism of activation of Ca2+ signaling, 
but two mutations in the Na+/K+-ATPase, p.Leu104Arg and p.Val332Gly, reportedly result in 
intracellular acidification, with no detectable increase in intracellular Ca2+ concentration, 
that causes the overproduction of aldosterone.45 Germline mutations in ATPases have not 
been described to date presumably because they are incompatible with life. 
Somatic CACNA1D mutations in APA 
Somatic APA mutations in CACNA1D that cause substitutions at conserved sites of 
Cav1.3 were first described in two reports.30,41 The mutations determine an impairment of 
the ion channel gating mechanism such that both activation and inactivation of the channel 
are affected and an increase in Ca2+ influx results.30,41 The number of different somatic APA 
mutations in CACNA1D are numerous with at least 31 substitution mutations of 25 different 
amino acid residues reported (Table S1). Somatic CACNA1D mutations are associated with 
APA of a smaller size41,44 and, with a reported prevalence of 9.3%, comprise the second 
largest group of APA after those with a KCNJ5 mutation.44 A highly selective antagonist of 
Cav1.3, 1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione has been 
developed as a potential novel therapeutic approach for Parkinson’s disease, displaying 600-
times selectivity over Cav1.246 and selective antagonism of Cav1.3 may be a target for the 
treatment of aldosterone overproduction in patients with PA.47   
Somatic CTNNB1 mutations in APA 
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The canonical Wnt (Wnt/β-catenin) pathway controls key developmental gene 
expression programs and constitutive activation of this pathway is involved in the 
pathogenesis of many human cancers. In the absence of extracellular Wnt ligands, glycogen 
synthase kinase 3b, as part of the multi-protein Axin complex, phosphorylates specific serine 
and threonine residues in the N-terminal region of b-catenin which is then degraded via the 
ubiquitin-proteosome pathway.48 Binding to the Frizzled/LRP (lipoprotein receptor-related 
protein) receptor inhibits the Axin complex and b-catenin is stabilized, accumulates and 
translocates to the nucleus to activate LEF/TCF (T-cell factor/lymphoid enhancer factor) 
transcription factors thereby activating Wnt target gene expression programs.48 
Activating somatic mutations in the CTNNB1 gene, that encodes β-catenin, have been 
reported at a similar prevalence in both adrenocortical adenomas (27% of 26 tumors, with a 
higher proportion in non-functioning adenomas compared with cortisol-producing 
adenomas) and adrenocortical carcinomas (31% of 13 tumors).49 Most mutations affected a 
phosphorylation site (Ser45) for glycogen synthase kinase 3b.  
A high proportion of APAs (70%) display constitutive activation of Wnt/β-catenin 
signaling that is caused, at least partly, by a decrease in the expression of SFRP2 (Secreted 
Frizzled Related Protein 2) an endogenous inhibitor of Wnt/β-catenin signaling.50 Somatic 
mutations in the CTNNB1 gene have been identified in 2-5% of APA.51,52 All mutations target 
exon 3 and almost all affect serine and threonine residues at the β-catenin N-terminus 
resulting in an accumulation of β-catenin. Therefore, β-catenin mutations are present in APA 
as in other adrenocortical tumors where they play a role in adrenocortical tumorigenesis.  
Somatic APA CTNNB1 mutations have also been described in 2 pregnant women and 
a woman post-menopause with highly up-regulated adrenal expression of luteinizing 
hormone/choriogonadotropin receptor and gonadotropin releasing hormone receptor 
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leading to the suggestion that pregnancy could trigger the overexpression of these 
gonadotropin receptors via a mechanism mediated by constitutive activation of β-catenin.53  
Histopathology of aldosterone production  
The development of specific monoclonal antibodies against the key steroidogenesis 
enzymes CYP11B2 and CYP11B154 has transformed the interpretation of the histopathology 
of PA and identified a new histological structure called the aldosterone-producing cell cluster 
(APCC).55-58 APCCs are distinct clusters of zG cells identified by strong CYP11B2 
immunostaining and an absence of CYP17 staining and are located in the subcapsular 
portion of the adrenal cortex that penetrates into the cortisol-producing cells of the zF.54,59 
At least 1 APCC was identified in 69% of an autopsy series of 127 normal adrenals59 and 50% 
of 22 adrenals had an APCC in the tissue adjacent to an APA.60 The physiology of aldosterone 
production changes with age with a transition from continuous expression of CYP11B2 in the 
zG in the young to a discontinuous expression with an increased expression of APCCs in older 
subjects.59 The adrenals of children aged below 12 years show a conventional zonation of 
the adrenal cortex without APCCs61 with the earliest documented case of an APCC occurring 
in a 12 year old male.59 Transcriptome analysis of APCC and the 3 zones of the adrenal cortex 
demonstrated the highest expression of CYP11B2 in APCCs and the similarity of the APCC 
and the zG transcriptomes.62 
  A high proportion of APCCs in the normal adrenal glands from kidney donors carry 
mutations in genes that are mutated in APAs (35% of 23 APCCs have mutations in CACNA1D 
or ATP1A1) leading to the proposal that APCCs are precursors of APAs.62 Although APCC with 
KCNJ5 mutations, the most frequently recurring mutation in APAs, were not identified, a 
histological structure with a transitional phenotype from APCC (subcapsular region) to 
microAPA (outer region), called APCC-to-APA transitional lesions, have been described in 
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which KCNJ5 mutations were identified in the microAPA portion of the larger lesions 
(>3mm). This supports the hypothesis of the APCC to microAPA transition and suggests that 
KCNJ5 mutations could occur as a second genetic hit.61,63 The number of the reported 
transitional lesions are however few with 6 known cases to date.  
If present adjacent to an APA, the production of aldosterone from APCCs is 
presumably biochemically autonomous given the suppressed renin-angiotensin-system, but 
their contribution to aldosterone excess is likely to be negligible, since the APA is probably 
the main source of aldosterone production. However, in the normal adrenal cortex of elderly 
persons APCCs may be a driver of hypertension and contribute substantially to age-related 
cardiovascular risk.59 
APA display different patterns of CYP11B2 and CYP11B1 immunostaining that can be 
homogeneous and dominant for CYP11B2, heterogeneous for CYP11B2 and interspersed 
with patches of CYP11B1, or CYP11B2-negative.56,60 CYP11B2 immunoreactivity is 
significantly higher in microadenomas than in macroadenomas and patients with the smaller 
tumors display disproportionately higher levels of aldosterone production64 and CYP11B1 
immunostaining is associated with glucocorticoid overproduction in some APA.65  
The adrenal tissue adjacent to an APA can display micronodules or macronodules 
that can carry a somatic mutation of a different genotype to the APA.58,66,67 In some 
infrequent cases, a secondary nodule is the source of the excess aldosterone production and 
in these circumstances the adenoma is usually CYP11B2-negative.56,68 
Conclusion 
Advances in sequencing technologies and immunohistochemistry have advanced our 
understanding of the pathogenesis of PA and shown that the pathological production of 
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aldosterone in this most common form of endocrine hypertension is not as straightforward 
as classically contended. 
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PA subtype Genetic variant Affected  
protein 
Amino acid 
substitution 
 Clinical phenotype Treatment  
FH type I CYP11B1/B2 
chimaeric gene12 
CYP11B2 
regulated by 
ACTH in zF  
-  PA of variable severity, early onset; 
high frequency of stroke; 
overproduction of hybrid steroids* 
DEX 
FH type II Genetic linkage 
with chromosome 
7p2210 
Unknown Unknown  Indistinguishable from sporadic PA Unilateral ADX  
MRA 
FH type III KCNJ5 mutations GIRK4 Thr158Ala21 
Gly151Glu69  
Gly151Arg70 
Ile157Ser71 
Tyr152Cys72 
Glu145Gln73 
PA of variable severity, usually early 
onset 
Bilateral ADX 
MRA 
FH type IV CACNA1H 
mutations 
Cav3.2 †Met1549Val24 
 
Ser196Leu29 
Pro2083Leu29 
PA of variable severity, early onset 
with incomplete penetrance for 
Met1549Val variant 
Unilateral ADX  
MRA 
Sporadic PA KCNJ5 mutations GIRK4 Arg52His33 
Glu246Lys33 
Gly247Arg33 
#Glu282Gln33 
Indistinguishable from sporadic 
BAH/APA 
MRA 
Unilateral ADX 
Sporadic APA CACNA1H mutation Cav3.2 Val1951Glu29  Indistinguishable from sporadic APA Unilateral ADX  
PA and multiplex 
developmental 
disorder 
CACNA1H mutation Cav3.2 ‡Met1549Ile29  Early onset PA with mild mental 
retardation, social skills alterations 
and learning disabilities 
MRA 
PASNA CACNA1D 
mutations 
Cav1.3 ‡Gly403Asp30 
 
‡Ile770Met30 Early onset PA with neuromuscular 
abnormalities 
CCB 
MRA 
 
Table 1. Germline mutations associated with primary aldosteronism 
FH, Familial hyperaldosteronism; PA, primary aldosteronism; APA, aldosterone-producing adenoma; BAH, bilateral adrenal hyperplasia; 
PASNA, PA with seizures and neurologic abnormalities; CYP11B1, gene encoding 11b-hydroxylase; CYP11B2, gene encoding aldosterone 
synthase; ACTH, adrenocorticotropic hormone; zF, zona fasciculata; GIRK4, G protein coupled inwardly rectifying potassium channel 4; 
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Cav3.2, Ca2+ channel, voltage-dependent, T type, a 1H subunit; Cav1.3, Ca2+ channel, voltage-dependent, L type, a 1D subunit; DEX, 
dexamethasone; ADX, adrenalectomy; MRA, mineralocorticoid receptor antagonist; CCB, Ca2+ channel blocker. *The hybrid steroids are 
18-hydroxycortisol and 18-oxocortisol; †de novo mutation also identified,	‡de novo mutation; #rare nonsynonymous single-nucleotide 
polymorphism rs7102584 present in 12 of 251 patients (5%) with PA compared with 22 of 1075 individuals (2%) in the international 
1000 genomes cohort. In the 12 patients with PA carrying the rs7102584 (Glu282Gln) polymorphism, 9 were diagnosed with BAH and 3 
with APA.33 
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Figure 1. Germline and somatic mutations in GIRK4 associated with different forms of 
primary aldosteronism 
Different somatic and germline mutations are indicated in GIRK4 encoded by the KCNJ5 
gene.  
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Gene Protein Mutations* 
 
   
KCNJ5 GIRK4 Arg115Trp1 
Trp126Arg2 
Ala139_Phe142dup3 
Ile144_Glu145insAlaIle4 
Glu145Gln5 
Thr148Ile_Thr149Ser6 
Thr148_Thr149insArg7 
Thr149ins8 
Ile150_Gly151insMet4 
†Gly151Arg9 
Gly153_Gly164dup10 
Phe154Cys4 
Ile157del11 
Ile157Lys4 
Thr158Ala12 
†Leu168Arg9 
Glu246Gly1 
 
ATP1A1 Na+/K+ ATPase 1 Gly99Arg2 
Phe100_Leu104del13 
Met102_Leu103del14 
Met102_Ile106del14 
Leu103_Leu104del14 
Leu104Arg13 
Ile322_Ile325del15 
Ile327Ser15 
Val332Gly13 
 
Phe956_Glu961del14 
Phe959_Glu961del14 
Glu960_Leu964del14 
GluGluThrAla963Ser16 
 
ATP2B3 Ca2+ATPase 3 Tyr410Asp17 
Thr423_Leu425del14 
Val424_Leu425del18 
Val424_Val426del14 
Leu425_Val426del13 
Val426_Val427del13 
Val426_Val429del14 
Val426Gly_Val427Gln_Ala428_Leu433del4 
Val427_Ala428del19 
  
CACNA1D Cav1.3 Val259Asp16 
Val401Leu14 
Gly403Arg16 
Gly403Arg4 
Glu412Asp20 
Ser652Leu18  
Leu655Pro18 
Tyr741Cys18 
Phe747Leu16 
Phe747Val20 
Phe747Cys21 
Val748Ile10 
Ile750Met16 
Ile750Phe18 
Val752Gly20 
Phe767Val4 
Ile770Met22 
Val979Asp18 
Val981Asn18  
Arg990His16 
Arg993Ser20 
 
Ala998Ile18 
Ala998Val18 
Ala998Val20 
Val1151Phe18 
Ile1152Asn18 
Val1153Gly23 
Pro1336Arg16 
Val1338Met22 
Val1353Met14 
Met1354Ile16 
 
 
CTNNB1 b-catenin Ser33Cys24 
Gly34Arg24 
Ala39Glu.fs*34 
Thr41Ala25 
Ser45Phe24 
Ser45Pro25 
  
PRKACA cAMP dependent  
protein kinase a 
‡Leu206Arg26 
His88Asp26  
   
GNAS Guanine Nucleotide 
Binding Protein a 
‡Arg201Cys27 
 
   
 
Table S1. Somatic mutations associated with aldosterone-producing adenomas 
GIRK4, G protein coupled inwardly rectifying potassium channel 4; Cav1.3, Ca2+ channel, voltage-
dependent, L type, a1D subunit; Cav3.2, Ca2+ channel, voltage-dependent, T type, a1H subunit 
 
*To our knowledge, the above table shows all somatic mutations in aldosterone-producing 
adenomas reported to date. 
 
†Most frequently occurring mutations in aldosterone-producing adenomas 
‡Mutations also present in adenomas co-secreting cortisol 
 
 
 
 
